Key statistics dashboard for Mustang Bio, Inc. (MBIO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relap...
Stock Data
| Price | $0.50 |
| Market Cap | $4M |
| Enterprise Value | -$11.4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.11 |
| Price / Book | 0.45 |
| P/S | 0.00 |
| EV/EBITDA | 3.75 |
| EV/Sales | 0.00 |
| EV/FCF | 2.52 |
| P/FCF | -0.84 |
| Earnings Yield | -90.09% |
| FCF Yield | -119.06% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -34.23% |
| Return on Assets | -19.43% |
| Return on Invested Capital | -45.77% |
| Return on Capital Employed | -45.77% |
Financial Health
| Current Ratio | 1.97 |
| Quick Ratio | 1.97 |
| Cash Ratio | 1.91 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 5.00 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -31.16 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.12 |
| Cash per share | 2.25 |
| FCF per share | -0.67 |
| Tangible Book Value per share | 1.12 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 1.00 |
Related companies: ABP · ACXP · BOLT · DWTX · EVGN · IMRN · LYRA
Explore sector: Healthcare · Biotechnology
More sections of MBIO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks